Add to ORKGThe management of iron metabolism in recombinant human erythropoietin treated dialysis patients by Dutch nephrologist
In patients with chronic kidney disease, treatment with erythropoiesis-stimulating agents (ESA) effe...
Abstract The need for a renewable source of erythro- relation to the evolution of renal replacement ...
The aim of the study was to identify resistance to erythropoietin in patients with terminal chronic ...
Iron overload increases the risk of bacterial infection in dialysis patients, partly by impairing fu...
Much progress has been made in recent years in the management of anemia associated with chronic and ...
Iron supplementation is required in a preponderance of peritoneal dialysis (PD) patients treated wit...
The human recombinant erythropoietin (hrEpo) is crucial in anemia treatment options in chronic renal...
The primary cause of anemia in dialysis patients is inadequate production of erythropoietin (EPO) by...
Erythropoietin and renal transplantation. The advent of erythropoietin (rHuEPO) has revolutionized t...
Transfusion and recombinant human erythropoietin requirements diVer between dialysis modalitie
Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation...
Iron is a very important biogenous trace element, which is involved in many of cell processes in org...
Kidneys are the main site of production of the hormone erythropoietin (EPO) that is the major regula...
Treatment with erythropoiesis-stimulating agents (ESAs) enables the correction of anaemia in chronic...
SUMMARY A 59-year-old Caucasian male started intermittent hemodialysis in March 1995 for the treat-...
In patients with chronic kidney disease, treatment with erythropoiesis-stimulating agents (ESA) effe...
Abstract The need for a renewable source of erythro- relation to the evolution of renal replacement ...
The aim of the study was to identify resistance to erythropoietin in patients with terminal chronic ...
Iron overload increases the risk of bacterial infection in dialysis patients, partly by impairing fu...
Much progress has been made in recent years in the management of anemia associated with chronic and ...
Iron supplementation is required in a preponderance of peritoneal dialysis (PD) patients treated wit...
The human recombinant erythropoietin (hrEpo) is crucial in anemia treatment options in chronic renal...
The primary cause of anemia in dialysis patients is inadequate production of erythropoietin (EPO) by...
Erythropoietin and renal transplantation. The advent of erythropoietin (rHuEPO) has revolutionized t...
Transfusion and recombinant human erythropoietin requirements diVer between dialysis modalitie
Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation...
Iron is a very important biogenous trace element, which is involved in many of cell processes in org...
Kidneys are the main site of production of the hormone erythropoietin (EPO) that is the major regula...
Treatment with erythropoiesis-stimulating agents (ESAs) enables the correction of anaemia in chronic...
SUMMARY A 59-year-old Caucasian male started intermittent hemodialysis in March 1995 for the treat-...
In patients with chronic kidney disease, treatment with erythropoiesis-stimulating agents (ESA) effe...
Abstract The need for a renewable source of erythro- relation to the evolution of renal replacement ...
The aim of the study was to identify resistance to erythropoietin in patients with terminal chronic ...